

REMARKS

The substitute Sequence Listing enclosed herewith has been voluntarily amended to facilitate its administrative processing, and not for reasons related to patentability.

I hereby state that the amendments included in the substitute Sequence Listing are supported in the application, as filed, at least in the original Sequence Listing, for the amendments to SEQ ID NOs: 3, 4, 5, 6, 11, 14, 21, 27, 28, and 29. The amendments to <110> and <140> in the Sequence Listing reflect U.S. filing information. Thus, the substitute Sequence Listing does not include new matter.

A copy of the substitute Sequence Listing in computer readable form, along with the required Statement under 37 C.F.R. 1.821(g) and 1.825(b), are filed simultaneously herewith and serve as the response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (copy enclosed).

Please charge any necessary fees or credits to Deposit Account 04-1928 (E. I. du Pont de Nemours and Company).

In view of the foregoing, allowance of the above-referenced application is respectfully requested.

Respectfully submitted,



J. KENNETH JOUNG
Attorney For Applicants
Registration No. 41,881
Telephone: 302-992-4929
Facsimile: 302-892-1026

Dated: 26 July 2002

Enclosures: substitute Sequence Listing – 46 pages and CRF
copy of April 30, 2002 Notice to Comply